4-P-CHL0R0PHENYL-l-(3-p-fiuorobenzoylpropyl)-4-hydroxypiperidine (R. 1625, Haloperidol) is a new compound synthesized by Janssen et al. (1959) and reported to have biological properties similar to those of the phenothiazines at a much lower dosage level. One difference, however, was a greater tendency to potentiate pentobarbitone hypnosis. Von Eiff and Jesdinsky (1960) conducted a â€oe¿ double blindâ€• trial in 28 normal subjects using 4 mg. Haloperidol 2@ or 4@ hours before the experimental period. Subjective effects included fatigue or fatigue and agitation in females. The drug did not appear to influence intellectual function as tested, but reduced self-criticism. There were minor cardio-vascular effects and a tendency to fatigue in ergometry performances.
A number of clinical reports have appeared (Divry et a!., 1960; Delay et al., 1960) suggesting that Haloperidol is of value in psychomotor agitation and especially in mania in doses of 2â€"15mg. daily. Gerle (1960) reports favourably on the drug in schizophrenic patients. Most authors note a high incidence of pseudo Parkinsonian side-effects (40â€"80 per cent. of cases) and a section of a recent symposium on the drug in Belgium was devoted to â€oe¿ neurodysleptic syndromesâ€• (dystonic reactions, oculogyric crises, etc.) produced by it. Pichot (1960) at the symposium reported that these reactions can be controlled by chlorpromazine.
OBJECTS OF STUDY
It was decided, in the light of the information above, to design a trial which might show whether:
1. Haloperidol is therapeutically useful in chronic schizophrenics.
Haloperidol
is therapeutically useful in any particular sub-group of such patients. 3. Haloperidol is of any value in the treatment of any symptom or symptom complex in such patients.
4. The therapeutic properties are adversely affected by a slow build-up to the anticipated therapeutic dose.
5. Side-effects are lessened by a slow build-up to the anticipated therapeutic dose. 6. Chlorpromazine or other phenothiazines can protect against side-effects.
METHOD
Twenty withdrawn chronic schizophrenic patients in a group of long-stay wards were selected for the trial (Table I) to group 1 were all receiving prochlorperazine at the start of the trial; Group 3 were all receiving chlorpromazine ; Group 2 were not receiving drugs of any kind ; Group 4 consisted of the remainder and included two patients receiving reserpine and one chlorpromazine. The senior investigator controlled the prescription of drug and placebo in a â€oe¿ double blindâ€•cross-over design. As far as doses were concerned, two schedules were employed which predetermined a maximum rise each week. If the patient's clinical condition was satisfactory, or, alternatively, toxic manifestations were observed, then the doses could be adjusted below the permitted maximum. The schedules were designed to give a slow build-up of dose (â€oelow dosage scheduleâ€•) and a more rapid build-up (â€oehigh dosage scheduleâ€•).
The low dosage schedule permitted, using 3 mg. tablets: This phase also, therefore, occupied four weeks.
Patients in Group 1 were started on the low dosage schedule of the drug, Group 3 were started on the high dosage schedule of the drug. The drug was thus employed after courses of treatment with prochlorperazine and chlor promazine respectively. Groups 2 and 4 received placebo tablets in high and low doses respectively. At the end of a month all drug treated patients were changed to placebo without warning the staff, by simply substituting inert tablets and using the same labelling, etc. At the end of a further month the patients on Groups 1 and 3 were again treated with the drug at the last dose with which they had previously been treated. Those patients treated with placebo in the first month (Groups 2 and 4) were treated with the drug in the second month on high and low dosage schedules. In the third period they were put back on placebo without warning by simple substitution (Table II) . The trial was terminated in this form after ten weeks. Ratings were performed weekly by the second investigator and by the senior nursing staff using a standard interview technique (Baker and Thorpe, 1956 ) and a behaviour rating scale (Baker and Thorpe, 1956) respectively. In the latter case in order to restrict the ratings to personal observations, time sampling was employed and the nurses were asked to restrict their scoring to a set day each week when they were on duty. Not only were none of the raters aware of active and placebo treatment periods, but, in fact, they were also completely unaware of the true design of the trial. Before the study started they had been asked to pick ten matched pairs of patients for a concurrent study of two drugs. In each pair they were told one patient would receive one of the drugs and the second patient the other. Literature was issued showing the drugs to be similar in action and side-effectsâ€"and these were stressed. It was explained that there would possibly be quantitative advantages for one drug vis-Ã -vis the second. The objects of this deception were to prevent generalization from the recognition of side-effects by the raters and maintain the level of observer interest even if the drug were recognized. If side-effects reveal the drug in a drug-placebo design then clearly many advantages in a double-blind procedure are lost. If side-effects were recognized in this trial they would not mean to the raters that the patient was having something as opposed to nothing. Indeed, side-effects might be noticed in each of the groups that the raters had constructed because both these groups contained patients on the drug. If the raters tended to generalize from their observations they would pass advantages or disadvantages within the two groups they imagined were in use. These groups, in reality, contained random selections of drug and placebo patients because the real groups were chosen on entirely different criteria and thus advantages or disadvantages would go in a random fashion to drug and placebo.
Further information was obtained by a joint examination by both authors@ at monthly intervals, to elicit symptoms and from the statutory ward report books in which the nursing staff were encouraged to note anything unusual from day to day.
RESULTS
The nurses' behaviour ratings (Table III) show no inter-group differences which can be considered significant. If Groups 1 and 3, and 2 and 4, are con sidered together respectively, as patients previously treated and not previously treated with phenothiazines, then the nurses' rating shows an intra-group difference in phenothiazine-treated patients in the last fortnight of the trial as compared with the previous period on placebo (n=9: t=3 @ 1 : p=<O05). The doctor's standard interview scores (Table IV) show a number of inter-group differences which achieve accepted levels of significance. Comparing all drug treated with all placebo-treated patients in the first week of the trial and in the fourth week ofthe trial (for n =18 : t =2 . 2 and 2 45 respectively p = < .05) there is a reduction of scores favouring the drug. There is a similar result in the tenth week of the trial (n =18 : t =2 . 1 : p = < .05). Thus in patients previously treated with phenothiazines three of six comparisons show a significant reduction favouring the drug. In patients not previously treated there are no significant differences. Making intra-group comparisons, patients previously treated with phenothiazines show a significant reduction in mean scores for the standard interview, comparing the second month with the first month ofthe trial (n=9: t =2 .7 : p= <0 @ 05), and also comparing the last fortnight with the first month (n=9 : t=3 . 1 : p= <0 .05) In patients not previously treated there are n@ differences. Apart from any effect that the drug may have, it is possible that previously treated patients are those most capable of interaction with environ ment, and the intra-group changes are, in part at least, a training effect.
As far as the joint interview is concerned the symptom scores are shown in Table V at the start of the trial and at 4, 8 and 10 weeks. Symptoms were rated on a three-point scale, and the check list of symptoms used is given in Appendix A. Toxic symptoms were scored separately and these are shown in parenthesis. No significant differences could be shown between the reductions effected by drug and placebo in the symptoms of illness.
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Analysis of Ward Reports
Drug Period Placebo Period destructiveness (3), and the control of restlessness (1). Of these six four were regarded as catatonic and two as paranoid. Out of eight simple or hebephrenic patients treated none responded, whereas four of ten catatonics responded, as did both paranoids. Diagnostic sub-group evidently plays some part in determining response.
TOXIC EFFECTS
As far as toxic effects are concerned the position is summarized in Table VII .
TABLE VII Summary of Toxic Symptoms During Trial
It will be seen that 77 instances of toxic symptoms were nOted after Haloperidol as against 18 after placebo administration, and of the latter, ten instances were noted only a fortnight after Haloperidol and may thus represent a carry over effect.
After the low dosage schedule thirty instances of symptoms were noted at one month in ten patients treated. After the high dosage schedule twenty-nine were noted after a month's treatment.
Motor restlessness, variously called â€oe¿ the turbulence phaseâ€•and â€oe¿ akathisiaâ€•, has been observed after the administration of phenothiazines and reserpine and this symptom was examined in the first eight weeks of the trial to see whether it occurred in association with drug administration per Se, whether it was simply a feature of the schizophrenic process, or finally whether it occurred in association with other signs of drug intoxication. 
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Total and placebo. Three patients had oculogyric crises with or without dystonic phenomena. The first of these had been having reserpine before the trial, was on placebo for a month and was affected after 18 mg. Haloperidol in the high dosage schedule. The second and third patients were treated without incident in the first month in the high dosage schedule, having taken chlorpromazine up to this point. Their reaction occurred after 18 and 24 mg. respectively in a high dosage schedule after a month on placebo. There is no evidence however that other pseudo-Parkinsonian features (tremor, rigidity, etc.) enjoy a pro tective effect from previous phenothiazine administration.
In the first month seven patients were observed with pseudo-Parkinsonian features including one who already showed these features but became worse. Four of these were having chiorpromazine and three prochlorperazine before they started Halo peridol. Eight patients developed similar symptoms having been previously treated with placebo for a month.
CONCLUSIONS
Haloperidol is of limited value in the symptomatic treatment of long standing schizophrenic patients, and was most effective where the phenothiazines had already been thought to be indicated by the clinicians treating the patients studied. The symptoms affected favourably in the twenty patients concerned were aggressiveness and nocturnal incontinence, but of the six patients who derived most consistent benefit from the drug, two obtained this from the relief of stupor and the others from the control of aggressiveness, destructiveness and restlessness. The diagnostic sub-groups favourably affected were catatonic and paranoid schizophrenia.
A slow build-up of the drug to anticipated therapeutic doses does not appear to affect therapeutic properties adversely although overall these were, very limited. On the other hand, side-effects of the pseudo-Parkinsonian type were certainly not lessened by such a build-up. Oculogyric crises occurred in three patients, all on the high dose schedule and all early in treatment. One of the three had been safely treated with the low dosage schedule previously and two with the high dosage schedule after chlorpromazine.
The incidence of this acute side-effect may therefore have some relationship with the rapidity of the build up of the drug, and chlor promazine may possibly antagonize these effects. Haloperidol is apparently more neurotoxic than chlorpromazine or prochiorperazine, and apart from the pseudo-Parkinsonian and dystonic side-effects produces pallor and drowsi ness in a number of patients. A striking side-effect is motor restlessness, which appears to be associated with the appearance of pseudo-Parkinsonism.
The number of patients studied was small, but on the basis of this trial the only reasonable indications for Haloperidol at present seem to be phenothiazine sensitivity (in the toxic sense) or insensitivity (in the therapeutic sense) where the symptomatic picture or diagnosis would normally suggest the use of a phenothiazine drug. Further experience, on the other hand, may show the drug to retain usefulness in lower and less toxic doses than were employed here (up to 18 mg. daily), since some clinical effects have been observed with as little as 1+ mg. daily.
SUMMARY
A double-blind cross-over trial of Haloperidol was conducted on twenty long-stay schizophrenic patients. The results are described in terms of rating scales, symptom responses and diagnosis. Toxic effects of Haloperidol are enumerated and their prevention discussed.
